GN-CORPORATION
Nichi BRITE Beta glucan administration resulted in enhancement of immunity followed by reduction in biomarkers of pancreatic cancer and that of its recurrence in patients undergoing surgical resection of malignant pancreatic tumor, which was presented at the ASCO® Breakthrough meeting in Yokohama, Japan. IgA and CD209, markers of immunity enhanced while CA19-9, the marker of pancreatic cancer and CD44, that of cancer recurrence and severity, significantly reduced in patients who had Nichi BRITE, compared to the control group in the study by gastro-enterology surgeons and nutritional support team of Chikamori Hospital, Kochi, Japan. Importantly, the mean survival improved after Nichi BRITE administration.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807498226/en/
The Nichi BRITE Beta 1,3-1,6 Glucan is produced as an exo-polysaccharide by Aureobasidium Pullulans in a GMP certified facility in Japan and is water soluble. The subjects of Nichi BRITE group in the study were given 250mg Beta glucan as an active ingredient per day for 22 days as an adjuvant, while control group had a placebo instead; both groups were given standard of care treatment. The quantity consumed during the study by each patient is equivalent to four boxes of Nichi BRITE, which comes in a box of 24 sachets, 1.5-gram granule as content with 63 mg active beta glucan as ingredient per sachet. Oral administration was undertaken when possible, and when it was not possible, administration was through feeding gastrostomy or nasogastric tube. No adverse reactions were observed. The efficacy in terms of immune enhancement, cancer biomarker reduction and longer mean survival were reported with Nichi Brite as an adjuvant. (Graphic: Business Wire)
Pancreatic cancer has a very poor prognosis. Earlier data of Nichi BRITE allergen-free food supplement on safety and efficacy in improving the immune system, decreasing tumor size in animal models and improving NK cell cytotoxicity in healthy volunteers, elderly people and cancer patients formed the basis of this clinical study. In the study, Nichi BRITE beta glucans were administered from one-day prior to the surgery, until 21st post-operative day, either orally or through feeding gastrostomy. There were no adverse reactions with Nichi BRITE and the outcome was very encouraging, said Dr Akira Tsukada, Chief Hepato-biliary pancreatic surgeon.
The immune enhancement parameters increased in the Nichi BRITE consumed group compared to the control group. IgA level improved, which is the first line of defense against infections, and CD209 improved significantly, which represents monocyte derived dendritic cells that present foreign antigens for destruction by the immune system. Such immune enhancement, the researchers consider, has led to decline in CD44 cancer stem cells that cause metastases, reduction of pancreatic cancer marker CA19-9 and prolongation of lifespan evident by longer mean survival, confirming the multipronged advantages of Nichi BRITE.
While thanking Dr. Masanori Chikamori, Emeritus chairman for his initiatives, and Prof. Nobunao Ikewaki of Kyushu University of Medical Science who undertook the laboratory investigations, they recommend consideration of Nichi BRITE as a routine onco-nutrition supplement to be included in the clinical nutrition guidelines for patients undergoing surgical procedure for cancer and other conditions.
Nichi BRITE is not a drug or remedy to any illness and doesn’t carry any therapeutic claims. Research findings are for the understanding of healthcare professional and not to be construed as medical advice.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807498226/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CSC Digital Brand Services Announces Integration into CrowdStrike Falcon Adversary Intelligence’s Recon to Accelerate Detection and Enforcement Against Malicious Domains15.9.2025 23:27:00 CEST | Press release
CSC, the world’s leading enterprise-class domain registrar and online brand protection provider, announced today at Fal.Con 2025 a new integration of CSC’s domain security offerings with the CrowdStrike Falcon® cybersecurity platform. The integration with Recon, a core capability within Falcon Adversary Intelligence, enables organizations to accelerate the detection and takedown of malicious domains, reducing exposure to phishing, fraud, and brand abuse. As cybercrime reaches unprecedented levels, adversaries are increasingly exploiting digital assets, brands, and domain name system (DNS) infrastructure. Traditional defenses often overlook domain portfolios, leaving organizations vulnerable to spoofing, impersonation, and account takeovers. CSC and CrowdStrike are uniting to close this gap with a comprehensive solution that integrates advanced threat intelligence, rapid detection, and global enforcement. Through this integration, clients can: Leverage the Recon capability in Falcon Adv
Celonis Debuts at No. 3 on the 2025 Fortune Future 5015.9.2025 22:58:00 CEST | Press release
Celonis, a global leader in Process Mining, today announced it has been named to No. 3 on the 2025 Fortune Future 50 list, recognized among the world’s most promising companies poised for long-term growth. This marks the company’s first appearance on the list alongside a prestigious group of global innovators, and underscores its leadership in enabling successful AI and business transformation through Process Intelligence. Published annually in collaboration with the Boston Consulting Group, the Fortune Future 50 evaluates more than 2,000 public companies to identify those best positioned for sustained growth based on a proprietary system analyzing market potential, innovation, strategy, and investment in the future. “Being named to the Fortune Future 50 is powerful validation of the mission we’ve been on since day one - to make processes work for people, companies and the planet,” said Alex Rinke, co-CEO and co-founder of Celonis. “This is truly just the beginning of seeing how Proces
ElevenLabs-Powered Chroma Awards Opens Call For Submissions, With November 3 Deadline15.9.2025 15:00:00 CEST | Press release
Creator-Led Global AI Film, Music Video, and Games CompetitionUniting the Global AI Creative Community Chroma Awards, a groundbreaking AI Film, Music Video, and Games competition organized by ElevenLabs, the leading AI audio research and product company, announced today that submissions are open for its inaugural competition, with a November 3 deadline. Competition participants can access free trials of AI tools provided by sponsors starting today at https://pack.chromaawards.com/. The Chroma Awards was established with the mission to educate, empower, and spotlight the next generation of artists and showcase how AI can empower human creativity. The competition is organized by ElevenLabs and presented by Google Cloud, Freepik, fal, Dreamina AI, and CapCut. “Through this initiative we hope to unite creators, communities, and companies across the world to bring emerging technology and creative talent together in dialogue,” said Matty Shimura, Chroma Awards. “We’re incredibly grateful to
33 Innovators Join Morgan Stanley Inclusive & Sustainable Ventures Cohort15.9.2025 14:08:00 CEST | Press release
Accelerator’s expanded focus includes sustainable solutions and support for nonprofits 2025 cohort comprised of 33 early-stage innovators from the Americas and EMEA Five-month program to provide founders with $250,000 (£250,000), as well as mentorship and growth resources Morgan Stanley (NYSE: MS) today announced the global cohort of its Inclusive & Sustainable Ventures (MSISV). With founders from the Americas and Europe, the Middle East and Africa (EMEA), the 2025 MSISV cohort will support 29 startups in its Lab and four emerging nonprofits in its Collaborative, two in-house accelerators that will run over the next five months. Selected from thousands of applications, the 33 organizations will engage in a tailored entrepreneurship curriculum and receive mentorship and business-growth resources from Morgan Stanley’s ecosystem of internal and external partners. The firm will invest $250,000 (£250,000 in EMEA) in each startup and provide each nonprofit with a $250,000 grant. “Morgan Stan
Helmholtz Munich and Parse Biosciences GigaLab Generate World’s Largest Human Lung Tissue Perturbation Atlas15.9.2025 14:00:00 CEST | Press release
Researchers aim to identify cellular circuit mechanisms and generate a dataset to fuel AI-driven foundational research of lung biology Helmholtz Munich and Parse Biosciences today announced a strategic partnership to generate the world’s broadest lung disease perturbation atlas, powered by Parse Biosciences’ GigaLab platform. Using a human lung ex-vivo tissue slice culture model from normal control donor lungs as well as explant lung tissues from patients with chronic lung disease, the study aims to identify novel targets and cell circuits in lung health and disease by characterizing disease-specific responses of cells to 900 pharmacological interventions. Prof Herbert Schiller, Director of Helmholtz Munich’s Precision Regenerative Medicine Research Unit, and a leading researcher on lung biology and disease, will head this ambitious initiative. “Measuring the effects of drug treatments at single cell level directly in human lung tissue at scale, will help us to find strategies that imp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom